Actavis, Adamas win FDA approval for Alzheimer’s drug

Your Health Matters

(Reuters) – The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer’s patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc. Adamas shares were up nearly 17 percent at $17.10 in premarket trading. The drug, Namzaric is designed to treat moderate-to-severe dementia in Alzheimer’s patients by combining in a single capsule memantine and donepezil — ingredients in two drugs that are often prescribed together. Memantine is the active ingredient in Actavis’ Namenda, while donepezil is the active ingredient in Pfizer Inc’s Aricept. …
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave